We are live on ! Find out more
CAM

Cormorant Asset Management Portfolio holdings

AUM $1.99B
1-Year Est. Return 737.95%
This Fund
S&P 500
This Quarter Est. Return
-20.33%
1 Year Est. Return
+737.95%
3 Year Est. Return
+5,256.52%
5 Year Est. Return
+13,483.26%
10 Year Est. Return
+564,575.55%
AUM
$1.3B
AUM Growth
-$379M
Cap. Flow
+$105M
Cap. Flow %
8.09%
Top 10 Hldgs %
48.93%
Holding
86
New
8
Increased
9
Reduced
24
Closed
9

Top Buys

Rank Stock Value
1
GRNA
GreenLight Biosciences Holdings, PBC Common Stock
GRNA
+$60.1M
2
MLTX icon
MoonLake Immunotherapeutics
MLTX
+$28.4M
3
TPTX
Turning Point Therapeutics, Inc. Common Stock
TPTX
+$22.7M
4
APLS
Apellis Pharmaceuticals
APLS
+$22.1M
5
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$16.9M

Top Sells

Rank Stock Value
1
BEAM icon
Beam Therapeutics
BEAM
+$26.9M
2
ACRS icon
Aclaris Therapeutics
ACRS
+$13.1M
3
VERV
Verve Therapeutics
VERV
+$11.7M
4
CYTK icon
Cytokinetics
CYTK
+$10.7M
5
ZYME icon
Zymeworks
ZYME
+$9.83M

Sector Composition

Rank Sector Weight
1 Healthcare 98.33%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TPTX
1
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
$99.3M 7.63%
3,700,000
+675,000
+22% +$22.7M
ERAS icon
2
Erasca
ERAS
$6.15B
$90.3M 6.94%
10,505,554
+4
+0% +$46
DSGN icon
3
Design Therapeutics
DSGN
$751M
$83.3M 6.39%
5,156,994
-283,459
-5% -$4.34M
RXDX
4
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
$68.9M 5.29%
1,823,444
-24,580
-1% -$972K
GRNA
5
DELISTED
GreenLight Biosciences Holdings, PBC Common Stock
GRNA
$62M 4.76%
+6,710,540
New +$60.1M
APLS
6
DELISTED
Apellis Pharmaceuticals
APLS
$57.2M 4.39%
1,125,000
+500,000
+80% +$22.1M
RVMD icon
7
Revolution Medicines
RVMD
$38.5B
$50.9M 3.91%
1,995,066
-436,786
-18% -$9.51M
EWTX icon
8
Edgewise Therapeutics
EWTX
$4.28B
$45.4M 3.49%
4,682,874
+1,116,973
+31% +$14.4M
GLUE icon
9
Monte Rosa Therapeutics
GLUE
$1.82B
$42.1M 3.23%
3,002,199
– –
FMTX
10
DELISTED
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
$37.8M 2.91%
4,068,351
-571,644
-12% -$6.08M
RNAM
11
DELISTED
Avidity Biosciences
RNAM
$37.2M 2.85%
2,012,115
– –
TNGX icon
12
Tango Therapeutics
TNGX
$4.21B
$37.1M 2.85%
4,899,185
– –
JBIO
13
Jade Biosciences
JBIO
$1.18B
$33.6M 2.58%
52,305
– –
MLTX icon
14
MoonLake Immunotherapeutics
MLTX
$1.56B
$33.3M 2.55%
3,280,000
+2,850,000
+663% +$28.4M
TARS icon
15
Tarsus Pharmaceuticals
TARS
$2.55B
$23.1M 1.78%
1,375,982
-27,349
-2% -$508K
STOK icon
16
Stoke Therapeutics
STOK
$1.84B
$22.9M 1.76%
1,087,807
-94,555
-8% -$1.89M
CNTA
17
DELISTED
Centessa Pharmaceuticals
CNTA
$22.3M 1.71%
2,489,894
– –
CCXI
18
DELISTED
ChemoCentryx, Inc.
CCXI
$21.7M 1.67%
865,000
+465,000
+116% +$13.1M
AXNX
19
DELISTED
Axonics, Inc. Common Stock
AXNX
$20.2M 1.55%
322,240
– –
KRTX
20
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$19M 1.46%
+150,000
New +$16.9M
VRDN icon
21
Viridian Therapeutics
VRDN
$2.2B
$18.5M 1.42%
1,000,000
+700,000
+233% +$13.4M
VERV
22
DELISTED
Verve Therapeutics
VERV
$16M 1.23%
700,710
-408,514
-37% -$11.7M
BBIO icon
23
BridgeBio Pharma
BBIO
$16.4B
$15.9M 1.22%
1,568,909
-100,000
-6% -$1.03M
ACET icon
24
Adicet Bio
ACET
$77.6M
$15M 1.15%
46,875
– –
IMRX icon
25
Immuneering
IMRX
$262M
$14.9M 1.14%
2,302,626
– –
1
2 3 4

Similar funds

SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
RMCM
Reynders McVeigh Capital Management Boston, Massachusetts $1.98B AUM 23.37% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
CCA
Checchi Capital Advisers Beverly Hills, California $1.98B AUM 19.17% 1-Year Est. Return
LBC
Lowe Brockenbrough & Co Richmond, Virginia $2.01B AUM 22.05% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return

Cormorant Asset Management's Q1 2022 Portfolio in Review

As of Q1 2022, Cormorant Asset Management held 86 positions worth $1.3B, down 23% from $1.68B the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Cormorant Asset Management deployed $105M of net new capital in Q1 2022, opening 8 new positions and adding to 9 existing holdings. Its largest new stake was GreenLight Biosciences Holdings, PBC Common Stock: 6,710,540 shares worth $62M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 99% a quarter earlier.

On the sell side, the largest reduction was Beam Therapeutics, an estimated $26.9M trimmed.

  • Cormorant Asset Management's largest Q1 2022 buy was GreenLight Biosciences Holdings, PBC Common Stock: 6,710,540 shares worth $62M.
  • Cormorant Asset Management added most to MoonLake Immunotherapeutics in Q1 2022, an estimated $28.4M increase.
  • Cormorant Asset Management's biggest Q1 2022 reduction was Beam Therapeutics, cutting an estimated $26.9M.
  • Cormorant Asset Management fully exited Aclaris Therapeutics in Q1 2022, selling an estimated $13.1M.
  • Cormorant Asset Management's ten largest holdings make up 49% of its $1.3B portfolio in Q1 2022.
  • Cormorant Asset Management opened 8 new positions and closed 9 in Q1 2022.
  • Cormorant Asset Management's portfolio value fell 23% quarter-over-quarter to $1.3B.

Based on Cormorant Asset Management's 13F filing for Q1 2022, filed 16 May 2022.